X4 Pharma Q3 net loss narrows to $29.8 mln

X4 Pharmaceuticals

05/11/2025 12:23

Overview

X4 Pharmaceuticals Q3 net loss narrows to $29.8 mln from $36.7 mln yr ago

Company raised $240.3 mln in financing, extending cash runway to end of 2028

X4 Pharmaceuticals reports $13 mln annualized cost savings from workforce reduction

Outlook

X4 expects to complete 4WARD trial enrollment by Q3 2026

Company's cash runway extends to end of 2028

X4 plans to launch mavorixafor for chronic neutropenia by end of 2028

Workforce reduction expected to save $13 mln annually

Result Drivers

NET LOSS - Net loss for the three months ended September 30, 2025 was $29.8 million, or $0.69 for basic and diluted loss per share, compared to net loss of $36.7 million, or $5.48 for basic and diluted loss per share, for the same period in 2024

FINANCIAL STRENGTHENING - Raised $240.3 mln in financings, extending cash runway

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.69
Q3 Net Income
-$29.81 mln
Q3 Income from Operations
-$27.50 mln
Q3 Operating Expenses
$29.27 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $9.00, about 55.9% above its November 4 closing price of $3.97

Press Release: ID:nGNX21sz7z

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)